|
MYCO-007
MYCO-007 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders. It is a short-acting MDMA analogue. MYCO-007 is being developed by Mydecine. As of February 2024, it is in preclinical research. The chemical structure of MYCO-007 does not yet appear to have been disclosed. (MY100) and (MY101) were described in Mydecine's patent for short-acting MDMA analogues See also * MYCO-002 * MYCO-006 * List of investigational hallucinogens and entactogens This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmenta ... References Drugs with undisclosed chemical structures Entactogens Experimental entactogens Monoamine releasing agents {{Psychoactive-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Mydecine
Mydecine Innovations Group, or simply Mydecine, is an United States, American and Canada, Canadian pharmaceutical company that is developing psychedelic drug, psychedelics and entactogens as medicines. In August 2022, it was reported that Mydecine was experiencing financial difficulties and might cease operations. However, the company was able to obtain more funding and did not shutdown. Mydecine made the first legal import of magic mushrooms into Canada in 2021. Mydecine's drug candidates include the psychedelics psilocybin (MYCO-001, MYCO-003), MYCO-004 (a transdermal patch, patch-delivered tryptamine), and MYCO-005 (a novel aza-, aza psilocin structural analog, analogue with putatively better drug safety, safety) and the novel MDMA-like entactogens MYCO-002 (putatively safer), MYCO-006 (short-acting), and MYCO-007 (short-acting). Although the chemical structures of most of its drug candidates have not been disclosed, Mydecine has patented (MY100) and (MY101) as short-acting ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
List Of Investigational Hallucinogens And Entactogens
This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.'' The list also includes non-hallucinogenic drugs related to hallucinogens, such as non-hallucinogenic serotonin 5-HT2A receptor agonists and non-hallucinogenic ketamine analogues. Cannabinoids, or cannabinoid receptor modulators, are not included in this list. Many of the indications are not for continuous medication therapy but rather are for medication-assisted psychotherapy or short-term use only. The section that the drug is in corresponds to its highest developmental phase, not its phase for all listed indications. This list was last comprehensively updated in October 2024. It is likely to become outdated with time. Under development Preregistration * Midomafetamine (MDMA ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MYCO-002
MYCO-002 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders. It is said to be being developed towards the aim of improving the safety profile of MDMA. The drug is under development by Mydecine. It was patented in July 2021 and received breakthrough therapy designation from the Food and Drug Administration (FDA) in November 2021. As of November 2021, MYCO-002 is in the preclinical research for treatment of psychiatric disorders. The chemical structure of MYCO-002 does not yet appear to have been disclosed. See also * MYCO-006 * MYCO-007 * List of investigational hallucinogens and entactogens This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmenta ... References Drugs with undisclosed chemical structures Entactogens Experimental entactoge ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MYCO-006
MYCO-006 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders. It is a short-acting and fast-onset MDMA analogue. Based on animal studies, it is predicted that MYCO-006 will have a duration of 1 to 2hours, about one-third the 6- to 8-hour duration of MDMA, and to onset 4times as fast as MDMA. MYCO-006 is being developed by Mydecine. As of February 2024, it is in preclinical research. The chemical structure of MYCO-006 does not yet appear to have been disclosed. and were described in Mydecine's patent for short-acting MDMA analogues. See also * MYCO-002 * MYCO-007 * List of investigational hallucinogens and entactogens This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmenta ... References Drugs with undisclosed chemical structures Entac ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Entactogen
Entactogens, also known as empathogens or connectogens, are a class of psychoactive drugs that induce the production of experiences of emotional communion, oneness, connectedness, emotional openness—that is, empathy—as particularly observed and reported for experiences with MDMA. This class of drug is distinguished from the classes of hallucinogens or psychedelics and stimulants, although entactogens, for instance MDMA, can also have these properties. Entactogens are used both as recreational drugs and are being investigated for medical use in the treatment of psychiatric disorders, for instance MDMA-assisted therapy for post-traumatic stress disorder (PTSD). Notable members of this class include MDMA, MDA, MDEA, MDOH, MBDB, 5-APB, 5-MAPB, 6-APB, 6-MAPB, methylone, mephedrone, αMT, αET, and MDAI, among others. Most entactogens are phenethylamines and amphetamines, although several, such as αMT and αET, are tryptamines. When referring to MDMA and its cou ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MDMA
3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy (tablet form), and molly (crystal form), is an empathogen–entactogenic drug with stimulant and minor Psychedelic drug, psychedelic properties. In studies, it has been used alongside psychotherapy in the treatment of post-traumatic stress disorder (PTSD) and social anxiety in Autism, autism spectrum disorder. The purported pharmacological effects that may be Prosocial behavior, prosocial include altered sensations, increased energy, empathy, and pleasure. When taken by mouth, effects begin in 30 to 45 minutes and last three to six hours. MDMA was first synthesized in 1912 by Merck Group, Merck chemist Anton Köllisch. It was used to enhance psychotherapy beginning in the 1970s and became popular as a street drug in the 1980s. MDMA is commonly associated with dance party, dance parties, raves, and electronic dance music. Tablets sold as ecstasy may be Cutting agent, mixed with other substances such as ephedr ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Entactogen
Entactogens, also known as empathogens or connectogens, are a class of psychoactive drugs that induce the production of experiences of emotional communion, oneness, connectedness, emotional openness—that is, empathy—as particularly observed and reported for experiences with MDMA. This class of drug is distinguished from the classes of hallucinogens or psychedelics and stimulants, although entactogens, for instance MDMA, can also have these properties. Entactogens are used both as recreational drugs and are being investigated for medical use in the treatment of psychiatric disorders, for instance MDMA-assisted therapy for post-traumatic stress disorder (PTSD). Notable members of this class include MDMA, MDA, MDEA, MDOH, MBDB, 5-APB, 5-MAPB, 6-APB, 6-MAPB, methylone, mephedrone, αMT, αET, and MDAI, among others. Most entactogens are phenethylamines and amphetamines, although several, such as αMT and αET, are tryptamines. When referring to MDMA and its cou ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Psychiatric Disorder
A mental disorder, also referred to as a mental illness, a mental health condition, or a psychiatric disability, is a behavioral or mental pattern that causes significant distress or impairment of personal functioning. A mental disorder is also characterized by a clinically significant disturbance in an individual's cognition, emotional regulation, or behavior, often in a social context. Such disturbances may occur as single episodes, may be persistent, or may be relapsing–remitting. There are many different types of mental disorders, with signs and symptoms that vary widely between specific disorders. A mental disorder is one aspect of mental health. The causes of mental disorders are often unclear. Theories incorporate findings from a range of fields. Disorders may be associated with particular regions or functions of the brain. Disorders are usually diagnosed or assessed by a mental health professional, such as a clinical psychologist, psychiatrist, psychiatric ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Structural Analog
A structural analog, also known as a chemical analog or simply an analog, is a chemical compound, compound having a chemical structure, structure similar to that of another compound, but differing from it in respect to a certain component. It can differ in one or more atoms, functional groups, or substructures, which are replaced with other atoms, groups, or substructures. A structural analog can be imagined to be formed, at least theoretically, from the other compound. Structural analogs are often isoelectronicity, isoelectronic. Despite a high chemical similarity, structural analogs are not necessarily functional analog (chemistry), functional analogs and can have very different physical, chemical, biochemical, or pharmacological properties. In drug discovery, either a large series of structural analogs of an initial lead compound are created and tested as part of a structure–activity relationship study or a database is virtual screening, screened for structural analogs of a ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Preclinical Research
In drug development, preclinical development (also termed preclinical studies or nonclinical studies) is a stage of research that begins before clinical trials (testing in humans) and during which important feasibility, iterative testing and drug safety data are collected, typically in laboratory animals. The main goals of preclinical studies are to determine a starting, safe dose for first-in-human study and assess potential toxicity of the product, which typically include new medical devices, prescription drugs, and diagnostics. Companies use stylized statistics to illustrate the risks in preclinical research, such as that on average, only one in every 5,000 compounds that enters drug discovery to the stage of preclinical development becomes an approved drug. Types Each class of product may undergo different types of preclinical research. For instance, drugs may undergo pharmacodynamics (what the drug does to the body) (PD), pharmacokinetics (what the body does to t ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
